Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study.

Cancer research communications·2026
Same author

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Cell reports·2026
Same author

MYC serine 62 phosphorylation promotes its association with DNA double-strand breaks to facilitate repair and cell survival under genotoxic stress.

Genes & development·2026
Same author

Structure and function of the L-MYC N-terminus impacts strategies to inhibit the MYC family of oncoproteins.

The Biochemical journal·2026
Same author

CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer.

Oncogene·2026
Same author

The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A.

Nature communications·2026

Related Experiment Video

Updated: Jun 4, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer

Carolyn A Goard1, Richard G Mather, Balpreet Vinepal

  • 1Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

International Journal of Cancer
|February 26, 2011
PubMed
Summary

Lovastatin directly inhibits P-glycoprotein (P-gp) in multidrug-resistant (MDR) cancer cells, enhancing chemotherapy. Other statins showed limited or no P-gp interaction, highlighting differential effects for combination therapy.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: Jun 4, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Statins, known for cholesterol management, exhibit anticancer properties by inducing tumor cell apoptosis via the mevalonate pathway.
  • Multidrug resistance (MDR) in cancer, often mediated by P-glycoprotein (P-gp) efflux pumps, limits chemotherapy efficacy.
  • Lovastatin has shown MVA-independent modulation of drug accumulation in MDR cells, suggesting direct interaction with P-gp.

Purpose of the Study:

  • To investigate the direct interaction of four statins (lovastatin, atorvastatin, fluvastatin, rosuvastatin) with P-gp.
  • To evaluate the impact of these statins on P-gp-mediated drug efflux in human MDR tumor cells at clinically relevant concentrations.
  • To understand how statin-P-gp interactions influence the efficacy of chemotherapy drugs that are P-gp substrates.

Main Methods:

  • In vitro studies using purified P-gp to assess direct binding and inhibition kinetics.
  • Cell-based assays using human MDR tumor cells to measure drug accumulation (doxorubicin) and downstream effects (DNA damage, apoptosis).
  • Proteoliposome-based transport assays to evaluate P-gp substrate inhibition by statins.

Main Results:

  • Lovastatin demonstrated high-affinity direct binding to purified P-gp and significantly increased doxorubicin accumulation in MDR cells, enhancing cytotoxic effects.
  • Atorvastatin inhibited P-gp substrate transport in proteoliposomes but showed no effect on doxorubicin transport in MDR cells.
  • Flustvastatin and rosuvastatin exhibited minimal interaction with P-gp in vitro, even at high concentrations, and did not affect doxorubicin transport in MDR cells.

Conclusions:

  • Lovastatin directly inhibits P-gp, offering a potential strategy to overcome MDR and enhance chemotherapy efficacy.
  • Differential interactions of statins with P-gp necessitate careful consideration when integrating them into combination chemotherapy regimens.
  • Understanding these specific drug-transporter interactions is crucial for optimizing cancer treatment strategies involving statins and P-gp substrate drugs.